Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Indivior's Monthly Injectable Buprenorphine Wins Panel Backing; US FDA May Limit Dosage

Executive Summary

Advisory committee votes 18 to 1 for approval of the opioid abuse disorder treatment with restricted distribution; members advise post-market studies, registry.

You may also be interested in...



Indivior's Once-Monthly Buprenorphine Clears US FDA With Box Warning, REMS

Launch targeted for first quarter 2018 at price of $1,580 per monthly dose. Post-market requirements include study of 300 mg dose and use as initial treatment. Indivior also following health outcomes.

Keeping Track: Flurry Of Approvals Rolls Over Into Holiday Season

The latest drug development news and highlights from our US FDA Performance Tracker.

Sublocade Approval Grows Indivior's Opioid Addiction Franchise In Competitive Market

US FDA approval of Sublocade, the company's once-monthly buprenorphine depot injection, may help Indivior defend its opioid addiction franchise from generics and the competing Alkermes product Vivitrol. But another new rival is expected soon – a once-monthly product from Braeburn.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134043

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel